Abstract: Non-peptidic RGD-mimic ligands were designed and synthesized by click chemistry between an arginine-azide mimic and an aspartic acid-alkyne mimic. Some of these molecules combine excellent in vitro properties (high αvβ3 affinity, selectivity, drug-like logD, high metabolic stability) with a variety of radiolabeling options (e.g. tritium and [ 18 F]fluorine, plus compatibility with radio-iodination), not requiring the use of chelators or prosthetic groups. The binding mode of the resulting triazole RGD-mimics to αvβ3 or αIIbβ3 receptors was investigated by molecular modeling simulations. Compound 12 was successfully radiofluorinated and used for in vivo PET/CT studies in U87-tumour models, which showed only modest tumour uptake and retention, owing to rapid excretion. These results demonstrate that the novel click-RGD mimics are excellent radiolabeled probes for in vitro and cell-based studies on αvβ3 integrin, whereas further optimization of their pharmaco-kinetic and dynamic profile would be necessary for a successful use in in vivo imaging.
Introduction
Integrin αvβ3 is a heterodimeric transmembrane protein that belongs to the integrin superfamily receptors. [1, 2] This integrin subtype attracted considerable attention because it plays a key role in tumour angiogenesis, growth and metastasis, and in the last two decades it has become an established target for tumour treatment and diagnosis. [3, 4] Integrin αvβ3 is a receptor for multiple components of the extracellular matrix, including vitronectin, fibrinogen and fibronectin, that expose the Arg-Gly-Asp (RGD) tripeptide sequence. [5] The ligand-receptor recognition process is mainly regulated by the aspartic acid carboxylic group and the arginine guanidine group, both forming ionic interactions with a charged region of the protein. [6] These two moieties need to be separated by a 12-14 Å distance to allow the correct fitting into the αvβ3 binding pocket. [7] Although a number of high affinity RGD peptides have been described and some of them advanced to clinical trials, [8] RGD peptide mimics may offer significant advantages such as having better drug-like properties and allowing more flexibility in the exploration of optimized structure-activity-relationships with the receptor. [9] Structural modifications made on the linear pharmacophore consist of variation of the flanking amino acids and introduction of structural constraints, which were achieved by cyclization or by insertion of a rigid moiety (e.g. phenyl, isoxazole, 1,2,3-triazole rings and hydrazide bonds) in the flexible peptide sequence. [9] [10] [11] [12] [13] In fact, the reduction of conformational freedom towards a correct bioactive orientation favorably affects both activity and selectivity. From several studies focusing on the development of non-peptide RGD mimics, L-2,3-diaminopropanoic acid emerged as an optimal replacement of aspartic acid. Likewise, the substitution of the Arg guanidine function with less basic moieties a Supporting information for this article is given via a link at the end of the document.
(2-aminoimidazoles, 2-aminopyridines) has been proposed. [10, 11] To improve the pharmacological features of RGD peptides, a number of RGD peptidomimetics have been developed as therapeutic agents. [14] However, relatively few studies have investigated the use of these molecules as radiotracers. [15] [16] [17] [18] [19] [20] Kessler and co-workers assessed the potential of non-peptidic RGD mimics as PET imaging agents by equipping the integrin antagonists with a bifunctional chelator (NODAGA) and labeling with 68 Ga 3+ . [21] More recently, the direct radioiodination of non-peptide integrin ligands has been reported and the resulting tracers assessed as SPECT imaging agents. [22] In this study we designed small-molecule RGD-mimics that combine excellent biological properties (high affinity, selectivity, suitable logP value) with a variety of radiolabeling options not requiring the use of chelators or prosthetic groups. To this end, a small library of RGD peptidomimetics was synthesized and biologically screened to identify the chemical modifications that confer the highest αvβ3 affinity and selectivity against integrin αIIbβ3, which mediates platelet aggregation. The main features of these novel RGD mimics are: (a) α-N-(arylsulfonyl)-L-2,3-diaminopropanoic acid and 2-amino-3-methyl pyridine as Asp and Arg substituent, respectively; (b) a distance of about 13 Å between the acidic and basic groups in the predicted binding conformation; (c) a triazole ring as Gly mimetic, which confers favorable conformational restrictions to the linear scaffold and provides a versatile labeling site for the incorporation of tritium [23] and iodine [24] radioisotopes; (d) an electron-poor aromatic ring activated for 18 F-labeling via nucleophilic aromatic substitution [25] on the Asp-mimic portion (Figure 1 ). Notably, molecular modelling studies suggest that this fluorine atom may significantly contribute to the affinity and selectivity of these ligands through an attractive electrostatic interaction with the Tyr178 hydroxyl group of the αv subunit. 
Results and Discussion
Design and Synthesis. The copper-(I)-catalyzed 1,2,3-triazole cycloaddition allowed a convenient assembly of all the target compounds via "click chemistry" (Scheme 1). Two regioisomers (1 and 2) were initially prepared by swapping the orientation of the triazole ring ( Figure 2 ). The higher affinity ligand 1 was then selected for the optimization of the biological properties and the design of labeled derivatives 12 and 15. The synthesis of compound 1 and its analogues 9-16 (substituents shown in Table 1 ) is outlined in Scheme 1. The synthesis of the alkyne building blocks started from commercially available (S)-methyl-2-amino-3-(tert-butoxycarbonylamino)propanoate hydrochloride (3) that was reacted with arylsulfonyl chlorides 4a-d to give sulfonamides 5a-d. N-methylation of the sulfonamide function of 5a afforded the intermediate 5e. After acidic removal of the N-Boc protecting group from 5a-e, an amide-forming coupling was performed with propiolic acid, leading to the desired alkyne intermediates 6a-e. The click partners 8a-c were synthesized by alkylation of N-Boc protected 2-amino-3-methylpyridine 7. Coupling of alkynes 6a-e with azides 8a-c via CuAAC reaction afforded 1,2,3-triazole intermediates 17a-f and 17i. The iodinated 5-iodo-1,2,3-triazole analogues 17g-h were prepared by coupling alkynes 6a and 6c with the corresponding "click partners" 8c and 8b -respectively -in the presence of CuI, N-iodosuccinimide (NIS) and trimethylamine. Treatment of the methyl ester and N-Boc protected intermediates (17a-i) with LiOH followed by TFA afforded the desired products 1 and 9-16 (for structural details see Table 1 ). The regioisomer 2 was prepared by swapping the functionalization of the "click partners" relative to 1, namely incorporating the azide moiety on the Asp-mimic fragment 18 and the alkyne counterpart on the Arg-like side chain (19) . Alkyne 19 was prepared from 7 as already described. [23] The synthesis of the azide fragment 18 was accomplished by coupling of azidoacetic acid with the amine 20, that was prepared according to the literature. [26] "Click"-cycloaddition of the azide 18 with the alkyne 19 gave the 1,2,3-triazole 21. Treatment of 21 with TFA afforded the desired deprotected regioisomer 2 (Scheme 2). To investigate the possibility of radio-iodinating these RGDmimics, preliminary studies were performed using cold nonradioactive conditions, applying a synthetic procedure reported by Årstad et al for the synthesis of imaging agents containing a 5-[ 125 I]Iodo-1,2,3-triazole group. [24] The click reaction between alkyne 6a and azide 8c was performed in the presence of a stoichiometric amount of CuCl2, TEA (1.5 equiv) and NaI (1 equiv). The reaction was monitored via LC-MS ( Receptor binding assays. The design of triazole containing RGD-mimics afforded a set of 10 molecules that were submitted to competition binding assays to determine their binding affinity toward integrin αvβ3 [27] and selectivity over the closely related integrin αIIbβ3. Results are reported in IC50 values (Table 1) . Cyclic c [RGDfK] was included in the tests as positive control in order to compare the new RGD mimics with a well-established rigid ligand. These tests showed that ligand length (n) has a significant impact on αvβ3 affinity (entries 1-3), and a propyl chain (n = 3, entry 2) was found to provide the optimal distance between the Asp-and Arg-mimetic fragments to allow a correct fitting of the ligand into the binding pocket. Interestingly, the activity on αvβ3 and the selectivity against αIIbβ3 seem to be strongly dependent on the substitution of the phenyl ring with fluorine and EWGs such as nitro (NO2) and trifluoromethyl (CF3) moieties (entries 4-6). An increased affinity (2 to 4-fold) and a remarkable improvement in selectivity (up to 36-fold) were, in fact, observed in this series of derivatives (compare entry 2 with 4-6). The IC50 values of iodinated peptidomimetics 14 and 15 compared with their non-iodinated analogues 1 and 12 revealed that incorporation of iodine on the triazole ring did not affect affinity and selectivity (entries 3 vs 7 and 5 vs 8). Conversely, the N-methyl sulfonamide derivative 16 showed a considerable drop in affinity (entry 9), confirming the crucial role that the free sulfonamide function -NHSO2-plays in ligand-receptor interactions. Comparison of the IC50 values of non-peptide ligands 12, 13 and 15 with that of c(RGDfK) reference peptide (entry 11) indicates a considerable increase of binding affinity for αvβ3 in this series of analogues (to almost 14-fold) as well as an enhanced selectivity over αIIbβ3. Molecular Modelling. To provide structural support to biological activity data shown in Table 1 , the binding mode of triazole RGDmimics to αvβ3 or αIIbβ3 receptors was investigated by molecular modeling simulations. Entries 1-10 were docked towards the crystallographic structure of each receptor, [6, 28] and lowest energy poses were further relaxed by extensive energy minimization.
Ligand theoretical affinity was computed by the MM-GBSA [29, 30] and XSCORE [31] methods providing a very good correlation with experimental inhibitory activity data (R 2 = 0.896 and R 2 = 0.662, respectively (see also Supporting Information). Notably, the predicted binding mode of RGD-mimics is highly comparable with that of the crystallographic RGD ligand, [6] since they establish canonical interactions with the αvβ3 receptor as observed for well-known inhibitors. However, molecular docking suggested that triazole RGDmimics 11, 12, 13 and 15 bearing a nitro group or fluorine atoms substituted at the phenyl ring are able to form an additional H-bond interaction with the side chain of Tyr178 (αv subunit) (Figure 3 ). This interaction has never been exploited before for improving the affinity of integrin inhibitors and, in agreement with biological activity data of Table 1 and theoretical binding affinity (see Supporting Information), it may be responsible for the higher inhibitory potency against the αvβ3 receptor displayed by these molecules. Most notably, Try178 is missing on the αIIbβ3 receptor, where it is replaced by Phe160 that is however unable to establish H-bond interactions with these RGD-mimics, thus providing a structural explanation to the high selectivity for αvβ3 observed for 11, 12, 13 and 15. Iodine substitution is another unique feature of these triazole RGD-mimics, which was found to increase the binding affinity of 15 by experimental and molecular modelling studies (compare entry 5 with 8). Indeed, the iodine atom in 15, the most potent RGD-mimic of this series, is able to establish hydrophobic interactions with Tyr178 and Trp179 (αV) and Ala218 (β3 subunit). In contrast, iodine substitution in RGD-mimic 14, which bears a four-carbon linker, did not provide affinity gain, as the iodine is exposed to the solvent due to steric restrictions imposed by the length of the linker (compare entry 3 with 7, see also Supporting Information). The sulfonamide group of all molecules but 16 contacts the backbone of Asn215 and the side chain of Arg214 of the β3 subunit by Hbonds, thus providing a rational explanation for the loss of inhibitory activity observed upon methylation of the sulfonamide NH function (compare entry 2 with 9). For additional details on binding modes and theoretical affinities see the Supporting Information. Labeling. Based on the affinity data discussed above, compounds 12 and 15, which are fluorinated and iodinated versions of the initial lead 1, represent potential radiotracers for PET and SPECT imaging. Furthermore, tritiated versions could be useful tools for in vitro studies. We therefore investigated the synthesis of 12 and 15 in different radiolabeled forms (tritiation and radiofluorination). Tritiation. Compound 12 was successfully labeled with tritium (Scheme 4). To the best of our knowledge this is the first example of 3 Hlabeled non peptidic molecule able to bind integrin αvβ3, therefore [ 3 H]12 may represent a very useful tool for in vitro or ex-vivo studies on angiogenesis. The palladium-mediated dehalogenation was accomplished on the 5-iodotriazole 15 employing tritium gas in a tritium handling manifold in the presence of Pd/C and TEA (excess) in ethanol. Complete conversion of the iodinated starting material was obtained after 2.5 hours and the desired product was isolated by analytical HPLC with a radiochemical purity > 99% and a spec ific activity of 469 GBq/mmol. A logD (pH 7.4) = -0.55 was experimentally measured for [ 3 H]12 (see Supporting Information for details). The compound was evaluated in cells that are known to express no, moderate and very high levels of αvβ3 integrin. [32, 33] The magnitude of [ 3 H]12 binding to each cell line was consistent with αvβ3 expression levels ( Figure 4A ). Non-radiolabeled c(RGDfK) (10µM) was included to competitively block specific binding to αvβ3. This decreased [ 3 H]12 binding to PC3 and U87MG cells by approximately 60%, but had no effect in MCF7 cells ( Figure 4B ). The radiosynthesis was performed as a one-pot, two-step method using the Tracerlab FX-FN platform (GE Healthcare). For the initial step, a [K/Kryptofix222] + 18 F -complex was prepared and dried azeotropically under a stream of helium and vacuum at 110 o C. 90 GBq (n = 8) of product at the end of the radiosynthesis (EOS). The radiochemical purity was ≥99%, and the specific radioactivity was 248-281 GBq mol -1 (EOS). The total radiosynthesis time was approximately 80 min.
In vivo Imaging. Promising in vitro data and successful 18 F-radiolabeling prompted pilot in vivo analyses. Four mice implanted with U87 tumour xenografts on the back were subjected to PET/CT imaging with [ 18 F]12. Overall tumour retention of the tracer was low throughout the dynamic scan, whereas clearance was rapid, exhibiting both hepatobiliary and renal excretion. Uptake was initially high in the kidneys and liver but dropped off over the course of the 90 mins scan (Fig. 6) . By 10 mins most of the injected dose could be found in the urinary bladder, where by 90 mins virtually all of the activity could be detected (Fig. 6 A) . The low in vivo tumour uptake (0.9 ± 0.1%ID/g) and retention of [
18 F]12 appears to be partly due to low bioavailability resulting in rapid excretion. The rapidity of this process and lack of kidney retention suggest that the molecule is excreted unchanged without any prior metabolism. This hypothesis is supported by human and rat liver microsomal (HLM / RLM) stability tests performed on 12, whose half-life upon incubation with HLM and RLM at 37 ºC in the presence of the co-factor NADPH was very high, namely 770 and 470 min, respectively, as detected by LC-MS/MS analysis. In comparison, in similar U87-MG mouse xenograft models [
18 F]fluciclatide was reported to have a tumour-retention comprised between 1.28 ± 0.34 %ID/g and 1.88 ± 0.73 %ID/g (13 days later) 90 mins after injection. [34] Autoradiography. Sections of the U87-cells-derived tumors were mounted on slides and -after standard preparations -treated either directly with (Fig. 6B) , indicating specific binding to αvβ3 integrin comparable to that observed in in vitro studies. Expression of integrin αvβ3 in the U87 tumour xenografts used was confirmed by immunohistochemical staining (see Fig. S3 , Supporting Information). 
Conclusions
Novel small-molecule RGD mimics were designed and synthesized by click chemistry between an arginine-azide mimic and an aspartic acid-alkyne mimic. Some of these compounds displayed excellent in vitro properties (high αvβ3 affinity and selectivity, drug-like logD, high HLM/RLM stability), are amenable to radiolabeling with iodine, or tritium, or [ 18 F]fluorine, and do not require the use of chelators or prosthetic groups. Molecular modeling simulations provided an insight into the binding mode of these compounds to αvβ3 or αIIbβ3 receptors. Compound 12 was successfully radiofluorinated and used for in vivo PET/CT studies in U87-tumour models, which showed only modest tumour uptake and retention, partly owing to rapid excretion through the kidneys into urine. The results above demonstrate that the novel click-RGD mimics are excellent radiolabeled probes for in vitro and cell-based studies on αvβ3 integrin, whereas further optimization of their pharmaco-kinetic and dynamic profile will be required for a successful use in in vivo imaging via SPECT or PET/CT.
Experimental Section

Materials and instrumentation
Chemicals were purchased from Sigma Aldrich and Bachem. NMR spectra were recorded using a Bruker Avance-400 spectrometer equipped with a 5 mm single-axis Z-gradient quattro nucleus probe, operating at 376 MHz for 19 by HPLC was carried out on the same system equipped with a preparative reverse phase C18 column (Prodigy ODS-Prep, 10µm particle size; 250 x 10 mm i.d.; Phenomenex, UK). For the purpose of quality control, HPLC analysis was carried out on a Shimadzu prominence system operated using LabLogic software (Laura 3.0) and configured with a CBM-20A controller, LC-20AB solvent delivery system and SPD-20A absorbance detector. The system was equipped with a C18 Prodigy ODS(3) column, 5 µm particle size, 250 x 4.6 mm. Radioactivity was monitored with a radio-HPLC Bioscan Flowcount B-FC 3100 detector.
Chemistry.
Synthesis of 17e. Alkyne 6c (67.5 mg, 0.17 mmol, 1 equiv) and azide 8b (50 mg, 0.17 mmol, 1 equiv) were suspended in a mixture of tBuOH/H2O 2:1 (3 mL/mmol). CuSO4 (2%) and sodium ascorbate (10%) were added and the mixture was stirred at room temperature for 12 h. The reaction mixture was diluted with water, extracted with ethyl acetate (30 mL) three times and washed with brine. The collected organic phases were dried over Na2SO4, filtered and the solvent removed under vacuum. The crude mixture was purified by preparative thin-layer chromatography (PLC) (silica gel, n-Hex/EtOAc 4:6 as eluent) affording 96. 
Flow cytometry analysis of αvβ3 integrin expression
Cells were seeded at 0.35 x 10 6 cells/60 mm plate and grown for 72 h before the experiment. Cells were harvested from plates using cell dissociation reagent. αvβ3 cell surface expression was determined by flow cytometry as previously described, [33] using the LM609 antibody which binds selectively to αvβ3 integrin and detected with an Alexa Fluor 488 secondary antibody. Results are expressed as Median Fluorescence Intensity (MFI) of stained/ unstained cells (i.e. fluorescence in the presence/absence of αvβ3 antibody).
Radiotracer binding assays
Binding assays were performed as described in the literature. [27, 33] Automated synthesis of [ 18 
F]12
The automated synthesis of [ 18 
and the resultant mixture passed through a C18 SEP-PAK plus cartridge. The cartridge was rinsed with water (10 mL) and the product eluted with sterile ethanol (1 mL) and collected in sterile 0.9% saline (10 mL). Finally, the product was dispensed into a sterile vial via a 0.2 micron sterile filter for preclinical application. The radiochemical purity of the product was determined by HPLC using a C18 Prodigy ODS (3) column (5 µm particle size; 250 x 4.6 mm) eluted with ACN/water (35/65, v/v; 0.01% TFA) at a flow rate of 2 mL/min. The retention time for [ 18 F]12 was 8.6 min.
PET/CT imaging.
Four female cba nu/nu mice were implanted with 0.1mL of a 5x10 7 /mL suspension of U87 cells i/d on the back. Tumors were measured daily once since a palpable tumour became apparent. Once tumors reached approx. 500mm 3 , PET scans were performed to assess [ 18 F]12 tracer uptake and biodistribution. Mice were anaesthetized by placing in an induction chamber and turning the isofluorane to 2% (oxygen at 2L/min). Mice were transferred to an anesthetic facemask on a heated bed and settled for 5 minutes and the tail vein dilated and catheterized. Mice were then transferred to the temperature-controlled imaging bed and attached to the anesthetic facemask. After CT scanning, 10-15MBq [ 18 F]12 in a total volume < 200µL was injected i/v. Imaging commenced immediately after tracer injection, during which time body temperature and depth of anesthesia were monitored using readouts from the imaging bed. At the end of PET scanning, the mice will be removed from the scanner and sacrificed. Tumors were excised and sectioned for autoradiography and immunohistochemistry. Inveon acquired data: before reconstruction, the list-mode data were histogrammed with a span of 3 and maximum ring differences of 79 into 3D sinograms with 19 time frames (5 × 60 seconds (s), 5 × 120s, 5×300s and 4 × 300s) for image reconstruction. Images were reconstructed using the 3D-OSEM/MAP algorithm (4 OSEM3D iterations and no MAP iterations, with a requested resolution of 1.5mm). Regions of interest (ROIs) were drawn manually over tumors using Inveon Research Workplace software (Siemens, Germany) and further normalization was performed using the injected dose (from the dose calibrator) and animal weight to give a standardized uptake value (SUV). SUVmax was calculated from the maximum voxel value within the ROI and SUVmean as the average over all voxels.
Autoradiography
Sections of flash-frozen U87 tumors cut at 20m on a cryotome and mounted on slides were pre-incubated in Tris-NaCl at 4 o C for 5 mins. The slides were then incubated for 1 hour in Tris-NaCl plus ligands at room temp (50MBq of [ 
